

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1 NAME OF THE MEDICINAL PRODUCT

Carnation Verruca Caps 10% w/w medicated plaster  
Superdrug Verruca Treatment 10% w/w medicated plaster

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Salicylic Acid 10% w/w

For the full list of excipients, see section 6.1

### 3. PHARMACEUTICAL FORM

Medicated self-adhesive plaster with central well containing Salicylic Acid paste.

### 4 CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

Treatment of Verrucas

This medicine is indicated in adults and in children over 6 years.

#### 4.2 Posology and method of administration

##### Posology

One medicated dressing is applied over the affected area with the well filled with paste over the verruca,

##### *Paediatric population*

Treatment suitable for children over 6 years.

Children under 6 years are advised to consult their doctor prior to treatment.

##### *Elderly*

Adults over 50 years are advised to consult a doctor prior to treatment.

##### Method of administration

Apply the medicated dressing to the verruca with the well filled with paste over the verruca.

Retain in place for 2 days then remove.

Ensure any loose skin is gently scrapped away and the area is cleaned and dried. Reapply a fresh medicated dressing.

Repeat the procedure over an 8 day period.  
Apply a protective plaster dressing to the area to prevent infection and to allow healing.  
If the verruca is still present after four weeks, repeat the treatment.

#### **4.3 Contraindications**

Not to be used by diabetics or patients with severe circulatory disorders, except following a doctor's permission or recommendation.

Do not use if the verruca or surrounding skin is inflamed or broken

Do not apply to normal skin or use for any other purpose.

Hypersensitivity to the active substance or any of the excipients listed in section 6.1.

#### **4.4 Special Warnings and Special Precautions for Use**

Dressing should be removed if excess discomfort felt, or if patient is sensitised to dressing adhesive or central medication.

Verrucas are uncommon in patients over 50 years. The incidence of ischaemia in this group is much higher, which-can result in lesions and growths being mistaken for plantar warts. Patients over 50 years should consult a doctor before use.

Not to be used if patient has incipient gangrene.

#### **4.5 Interactions with other medicinal products and other forms of interaction**

The plaster should not be applied over other medication which has been applied to the skin as there is the potential for occlusion which may affect the action of the other medication.

Atropine is an antimuscarinic and may be absorbed. It has the potential for interacting with other drugs having similar affect such as antihistamines.

#### **4.6 Fertility, pregnancy and lactation**

There are no or limited amount of data from the use of this product during pregnancy.

Do not use this product during pregnancy, except for short-term treatment of a small single verruca.

It is not known if the systemic exposure of this product reached after topical administration can be harmful to an embryo / fetus.

During the third trimester of pregnancy, systemic use of prostaglandin synthetase inhibitors may induce cardiopulmonary and renal toxicity in the fetus. At the end of the pregnancy prolonged bleeding time in both mother and child may occur, and labour can be delayed.

#### **4.7 Effects on ability to drive and use machines**

Not relevant.

#### **4.8 Undesirable effects**

Mild discomfort or soreness may be experienced especially when used on weight bearing surfaces e.g. heel or ball of foot.

A localised irritant reaction may occur if applied to normal skin surrounding the verruca. This may be controlled by temporarily discontinuing use and by carefully applying only to the verruca when the treatment is resumed.

##### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard).

#### **4.9 Overdose**

Do not treat more than 3 warts at the same time. Whilst absorption is low via this route, it is beneficial to limit treatment to 3 warts in case undesirable sensitisation occurs.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic Group: Keratolytics, wart and anti-corn preparation, ATC code: D11AF

Salicylic acid has keratolytic properties. Applied externally it attacks the intercellular matter between keratin molecules causing the cornified Epithelium to swell, soften and shed.

The epidermis desquamates making the underlying layer more accessible to debridement.

### **5.2 Pharmacokinetic Properties**

Formulation is designed to provide gradual release of Salicylic acid to restricted area of the verruca. It is absorbed into the outer epidermis.

### **5.3 Preclinical safety data**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sasolwax 3279

Softisan 378

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf-Life**

60 months

### **6.4 Special Precautions for Storage**

Store away from direct sources of heat or humidity.

Store at less than 30°C.

### **6.5 Nature and contents of container**

Each plaster is packed in a polypropylene/metallised polypropylene laminate bag.

Pack sizes:

Package with 1 plaster of 9.5 x 12.5 cm, 2 packs packed into an outer carton.

Package with 1 plaster of 28 x 17.5 cm

### **6.6 Special precautions for disposal**

No special requirements for disposal.

## **7. MARKETING AUTHORISATION HOLDER**

Cuxson Gerrard & Company Limited  
125 Broadwell Road  
Oldbury  
West Midlands  
B69 4BF  
United Kingdom

**8.     MARKETING AUTHORISATION NUMBER(S)**

PL 00089/0008

**9     DATE OF FIRST AUTHORISATION/RENEWAL OF THE  
AUTHORISATION**

Date of first authorisation: 14 July 1988

Date of latest renewal: 17 January 2008

**10    DATE OF REVISION OF THE TEXT**

07/01/2025